Build status - In Progress

A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
Recruiting
18 years - 65 years
All
Phase 2
5 participants needed
1 Location

Brief description of study

The purpose of this research study is to: 1) evaluate how well IMR-687 is tolerated in subjects with β-thalassemia and how safe it is, 2) measure the amount of IMR-687 in your blood and 3) evaluate what the drug does to the red blood cells and other blood markers associated with your disease.

Drug IMR-687 is not FDA approved for use.

This study will look at two different dose levels of IMR-687 and compare how these work to a placebo, which is a substance that looks like an active drug but has no active drug in it.

This study is a randomized trial which means that participants will be randomly assigned to one of the study drug doses (high dose or low dose of IMR-687, or placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: beta-thalassemia
  • Age: 18 years - 65 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 844255

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center